Item 7.01 Regulation FD Disclosure.

On September 15, 2021, Landos Biopharma, Inc. issued the press release furnished herewith as Exhibit 99.1 to announce that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation on November 6, 2021 at the American College of Rheumatology Convergence 2021.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits





99.1      Press Release of Landos Biopharma, Inc., dated September 15, 2021

104     The cover page from Landos Biopharma, Inc.'s Form 8-K filed on
        September 17, 2021, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses